Market Overview

ImmunoGen Announces Positive Results from Kadcyla Phase III Trial, TH3RESA at ECC 2013


ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops
novel anticancer therapeutics using its antibody-drug conjugate (ADC)
technology, announced the results from Roche's TH3RESA Phase III trial
being presented today at the European Cancer Congress (ECC) in Amsterdam
(abstract #LBA15). The findings were accepted as late-breaking data and
also included in the Congress's official press program.

The TH3RESA study assessed Kadcyla (ado-trastuzumab emtansine) for the
treatment of advanced HER2-positive breast cancer that had progressed
despite prior treatment with at least two HER2-targeted medicines. At a
minimum, patients must have received Herceptin® (trastuzumab), Tykerb®
(lapatinib), and a taxane. The trial included approximately 600 patients
who were randomized, on a two-to-one basis, to receive either Kadcyla or

See full press release

Posted-In: News Guidance Management Global


Related Articles (IMGN)

View Comments and Join the Discussion!